Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 305 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard of Care Antibiotic Therapy Clear all
Withdrawn No phase listed Observational Accepts healthy volunteers

Knee Prosthetic Joint Infection Antibiotic Elution

NCT06023238
View directory record Official record
Conditions
Prosthetic-joint Infection, Arthroplasty Complications
Interventions
Treatment of Chronic TKA PJI
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Recruiting Phase 4 Interventional

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

NCT03014687
View directory record Official record
Conditions
Antibiotics, Pituitary Adenoma
Interventions
Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 84 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

NCT01825408
View directory record Official record
Conditions
Sinusitis
Interventions
Doxycycline, Azithromycin, Augmentin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 28, 2026, 7:51 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

NCT03148756
View directory record Official record
Conditions
Endocarditis, Bacteremia
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 28, 2026, 7:51 PM EDT
Terminated Phase 4 Interventional Results available

Superficial Partial-Thickness Burn Study

NCT04601532
View directory record Official record
Conditions
Superficial Partial Thickness Burn
Interventions
Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser, Silver Sulfadiazine
Device · Drug
Lead sponsor
J. Peter Rubin, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

NCT02027428
View directory record Official record
Conditions
Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions
Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
91
States / cities
Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 28, 2026, 7:51 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age

NCT05345457
View directory record Official record
Conditions
Pregnancy Preterm, Pregnancy Prom, PROM, Preterm (Pregnancy), PROM (Pregnancy), Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/Labor, Premature Birth
Interventions
Azithromycin Pill, Amoxicillin Pill
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Terminated Phase 2 Interventional Results available

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

NCT03970200
View directory record Official record
Conditions
Severe Clostridium Difficile Infection, Severe-Complicated/Fulminant Clostridium Difficile Infection
Interventions
Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003, Antibiotics
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT03233438
View directory record Official record
Conditions
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Interventions
Dalbavancin, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Not applicable Interventional

The Utility of Urinalysis Prior to In-Office Procedures

NCT03526484
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Standard of Care, Experimental
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 28, 2026, 7:51 PM EDT
Terminated Phase 2 Interventional Results available

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

NCT04186247
View directory record Official record
Conditions
Crohn Disease, Pediatric Crohns Disease
Interventions
Azithromycin, Metronidazole, Standard of Care
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

NCT03462459
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
Interventions
Vancomycin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 28, 2026, 7:51 PM EDT
Recruiting Phase 2 Interventional

Antibiotic Tumescent For Chronic Wounds

NCT06327113
View directory record Official record
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional

Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis

NCT06005168
View directory record Official record
Conditions
Surgical Prophylaxis
Interventions
Cefazolin for Injection
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

NCT01659866
View directory record Official record
Conditions
Infection
Interventions
Ciprofloxacin, trimethoprim-sulfamethoxazole, cefuroxime, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
563 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

NCT04502095
View directory record Official record
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 28, 2026, 7:51 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

Management of Sub-Clinical Bacteriuria in Pregnancy

NCT03275623
View directory record Official record
Conditions
Cystitis, Cystitis;Puerperium, Pyelonephritis
Interventions
Antibiotic, Standard Prenatal Care
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 28, 2026, 7:51 PM EDT
Completed No phase listed Observational

Benefits of Universal Glove and Gowning

NCT01318213
View directory record Official record
Conditions
MRSA, VRE
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 28, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

Acute Application of Antibiotic Powder in Open Fracture Wounds

NCT04872400
View directory record Official record
Conditions
Fractures, Open, Wounds and Injuries--Infections, Anti-Bacterial Agents, Fractures, Bone, Extremity Fracture Lower, Extremity Fractures Upper
Interventions
Vancomycin, Tobramycin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Recruiting Early Phase 1 Interventional

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

NCT03439865
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Ivacaftor, standard of care treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 7:51 PM EDT
Not yet recruiting Phase 3 Interventional

Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:

NCT07458230
View directory record Official record
Conditions
Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
Interventions
NGS diagnostic findings
Diagnostic Test
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 28, 2026, 7:51 PM EDT